- Clinically meaningful anti-tumor activity of ZL-1310 observed in heavily pretreated population of patients with small cell lung cancer (SCLC) across dose escalation and expansion cohorts - In second ...

Zai Lab (NasdaqGM:ZLAB) shares have drifted steadily lower over the past month, as investors weigh the company’s ongoing growth prospects against a challenging period for biotech stocks. Despite ...

Zai Lab collaborated with NovoCure on a study to treat non-small cell lung cancer. There were some concerns about the validity of the study. Zai Lab improved revenue by 36% year over year in the first ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced financial results for full-year 2023, along with recent product highlights and corporate ...

SHANGHAI & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that it will report its fourth quarter and full year 2024 financial results and provide recent ...

Zai Lab is a commercial-stage biotech that saw revenue rise 33%, year over year, in the last quarter. The company is partnering with Swiss pharmaceutical Novocure on using Tumor Treating Fields to ...

Zai Lab (ZLAB) announced on Wednesday that it plans to await the results of a trial evaluating Bemarituzumab in combination with Nivolumab and chemotherapy before filing for regulatory approval of the ...

Zai Lab is set to reach several product milestones this year, as at least eight new products are on track for approval by the end of 2025. With $1 billion in cash reserves, the company has sufficient ...